OTC Markets OTCQB USD

Northwest Biotherapeutics, Inc. (NWBO)

0.2000

+0.0050

+(2.56%)

At close: April 10 at 4:00:00 PM EDT

Northwest Biotherapeutics: Q3 Earnings Snapshot

BETHESDA, Md. AP) — Northwest Biotherapeutics Inc. NWBO) on Tuesday reported a loss of $19.4 million in its third quarter.

Associated Press Finance 4 months ago

NWBO
+2.56%
Northwest Biotherapeutics: Q2 Earnings Snapshot

BETHESDA, Md. AP) — Northwest Biotherapeutics Inc. NWBO) on Friday reported a loss of $17.9 million in its second quarter.

Associated Press Finance 7 months ago

NWBO
+2.56%
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024.

PR Newswire 9 months ago

NWBO
+2.56%
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP). The technologies are already in Phase 2 clinical trials, and the Company plans to collaborate with the lead scientist-clinician, Dr. Pawel Kalinski, on

PR Newswire 9 months ago

NWBO
+2.56%

Performance Overview

Return	NWBO	S&P 500 (^GSPC)
YTD	-25.93%	-10.43%
1-Year	-61.54%	+2.08%
3-Year	-77.27%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics: Q3 Earnings Snapshot

Northwest Biotherapeutics: Q2 Earnings Snapshot

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

Performance Overview